Kalaris Therapeutics Inc. (KLRS) Upgraded to Buy: Here's What You Should Know

Core Viewpoint - Kalaris Therapeutics Inc. (KLRS) has been upgraded to a Zacks Rank 2 (Buy) due to an upward trend in earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system is based on changes in earnings estimates, which are closely correlated with near-term stock price movements [4][6]. - Rising earnings estimates for Kalaris Therapeutics indicate an improvement in the company's underlying business, likely leading to increased stock prices [5][10]. Zacks Rating System - The Zacks Rank stock-rating system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have averaged a +25% annual return since 1988 [7][9]. - Kalaris Therapeutics' upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [10]. Recent Earnings Estimate Revisions - For the fiscal year ending December 2025, Kalaris Therapeutics is expected to earn -$3.88 per share, unchanged from the previous year, but the Zacks Consensus Estimate has increased by 51.5% over the past three months [8].